Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seq-Cabo
NCT05931393Phase 2Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Dec 2023
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in renal cell carcinoma (RCC), sponsored by UT Southwestern Medical Center. Primary endpoint: Progression-Free Survival at 24 months. Started Dec 2023; status: recruiting.
02
Drugs
cabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05931393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05931393.